

GYNECOLOGY DISEASE SITE COMMITTEE

DISEASE SITE COMMITTEE MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON

ROOM: SCOTT

SATURDAY MAY 4, 2024 8:30 AM– 12:00 PM EST

CO-CHAIRS : MARK CAREY AND STEPHEN WELCH
SENIOR INVESTIGATOR: WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical trial and translational research, the disease burden associated with gynaecological malignancies in Canada.
- To identify clinical trial research opportunities within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct.
- To apply best practices in clinical trials conduct and analysis to the Canadian Cancer Trials Group research agenda.
- To identify mentoring opportunities within the Canadian Cancer Trials Group research agenda for new investigators.

8:30 am **Welcome / Announcements** M. Carey / S. Welch

8:35 am **PM.2/CAN-IMPACT-IO** L. Siu

8:45 am **Cervical Cancer Working Group Update** E. Leung / V. Samouelian

Approved trials:

- VU.2 / STRIVE
- CX.6 / SENTICOL

Closed trials:

- CX.5 / SHAPE – Economic Analysis

K. Han

New concept:

- ctDNA-Directed Adjuvant Therapy for LACC



9:30am	Endometrial Cancer Working Group Update	J. McAlpine / K. Han
	Approved trials: <ul style="list-style-type: none"> • EN.10 / TAPER-RAINBO Blue • EN.11 / RAINBO-Green 	
	New concepts: <ul style="list-style-type: none"> • RAINBO-Orange • PRIMER • Advanced / Metastatic post-IO concept 	J. Ethier E. Leung H. Mackay
10:15 am	Break	
10:30 am	Ovarian Cancer Working Group Update	S. Lau / A. Tinker
	Ovarian Cancer Trial Development Group	
	Closed trials: <ul style="list-style-type: none"> • OV.25 • OV.26 • OVC.1 • OVC.2 	
	New concept: <ul style="list-style-type: none"> • NRG-GY036 	A. Tinker
11:00 am	IND Committee Update	J. Ethier
	<ul style="list-style-type: none"> • IND.240 • IND.243 	
11:30 am	Standing Committee Liaison Reports	
	<ul style="list-style-type: none"> • Correlative Science / Tumour Bank (CSTB) • Quality of Life (QOL) • Economic Analysis (CEA) 	H. MacKay I.Kong J. Kwon
12:00 pm	Discussion / Meeting Adjourned	



GYNE Publications
January 2023 – April 2024

1. Plante, M., et al., Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. *New England Journal of Medicine*, 2024. 390(9): p. 819-829.
2. Mahner, S., et al. Surgical approach, preoperative LEEP/cone biopsy and patterns of recurrence and death in low-risk cervical cancer – analysis of the international CCTG CX.5/SHAPE phase III trial. in *ESGO Congress*. 2024. Barcelona, Spain: *International Journal of Gynecological Cancer*.
3. Kwon, J.S., et al. Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer from the CCTG CX.5 ‘SHAPE’ phase III clinical trial. in *ESGO Congress*. 2024. Barcelona, Spain: *Journal of Gynecological Cancer*.
4. Plante, M., et al. An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE). in *Journal of Clinical Oncology*. 2023.
5. Nohová, I., et al., Patient involvement in research within the Gynecological Cancer InterGroup: A call to action for a systematic approach: Results from a survey. *Health Science Reports*, 2023. 6(12): p. e1735.
6. McAlpine, J., et al. CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER. in *Journal of Clinical Oncology*. 2023.
7. Leath, C., et al. Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. in *Journal of Clinical Oncology*. 2023.
8. Karamouza, E., et al., CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. *Cancers*, 2023. 15(6): p. 1823.
9. Ferguson, S.E., et al. SEMINAL: A randomized trial comparing radical hysterectomy versus simple hysterectomy on sexual health, menopausal symptoms, and quality of life in patients with low-risk early-stage cervical cancer (SE011). in *International Gynecologic Cancer Society (IGCS)*. 2023. Seoul, Korea.
10. Ferguson, S.E., et al. SEMINAL: An international randomized phase III trial comparing radical hysterectomy vs simple hysterectomy in patients with low-risk early-stage cervical cancer (SE001). in *International Gynecologic Cancer Society (IGCS)*. 2023. Seoul, Korea.
11. Eskander, R.N., et al., Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. *New England Journal of Medicine*, 2023. 388(23): p. 2159-2170.

